The FDA has cleared donanemab-abzt, branded as Kisunla, to treat adults with early symptomatic Alzheimer’s disease, including people with mild cognitive impairment and those in the mild dementia ...
Eli Lilly announced on 2 July 2024 that the US Food and Drug Administration (FDA) has approved its anti-amyloid beta (Aβ) monoclonal antibody (mAb) Kisunla (donanemab) for the treatment of ...